CIPLA's weekly performance was disappointing, with a return of -1.25%, indicating a decline in stock value. The stock's volatility was moderate at 14.03%, which is relatively lower compared to its peers. In comparison to its peers, CIPLA underperformed SUNPHARMA but outperformed GRASIM, while being on par with DIVISLAB. The stock's risk profile was moderate, with a Sharpe Ratio of -0.35 and a Max Drawdown of -2.04%. 

[Volatility: 14.03%]